Factors determining the percentage of hypochromic red blood cells in hemodialysis patients

Kidney International

Volumn 56, Issue 3, 1999, Pages 1113-1119

  Bovy, Christophe ^a   Tsobo, Chantal ^a   Crapanzano, Linda ^a   Rorive, Georges ^a   Beguin, Yves ^a   Albert, Adelin ^a   Paulus, Jean Michel ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anemia; Chronic renal failure; Dialysis; Erythropoietin; Iron deficiency; Red blood cells; Soluble transferrin receptor

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; FERRITIN; IRON; PARATHYROID HORMONE; TRANSFERRIN; TRANSFERRIN RECEPTOR; UREA;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; ERYTHROCYTE COUNT; FEMALE; HEMODIALYSIS; HUMAN; IRON DEFICIENCY ANEMIA; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETICULOCYTE COUNT;

EID: 0032851407     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00627.x     Document Type: Article

References (38)

1. 1. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ 199:157-158, 1989
2. 2. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35:712-716, 1989
3. 3. Eschbach JW, Downing MR, Egrie JC, Browne JK, Adamson JW: USA multicenter clinical trial with recombinant human erythropoietin. Contrib Nephrol 76:160-165, 1989
4. 4. Eschbach JW, Adamson JW: Recombinant human erythropoietin: Implication for nephrology. Am J Kidney Dis 11:203-209, 1989
5. 5. Sunder-Plassman G, Hörl WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995
6. 6. Macdougall IC: Poor response to erythropoietin: Practical guidelines on investigation and management. Nephrol Dial Transplant 10:607-614, 1995
7. 7. Baynes RD: Assessment of iron status. Clin Biochem 29:209-215, 1996
8. 8. Gokal R, Millard PR, Weatherall DJ, Callender STE, Ledingham JGG, Oliver DO: Iron metabolism in haemodialysis patients. Q J Med 48:369-391, 1979
9. 9. Bell JD, Kincaid WR, Morgan RG, Bunce H, Alperin JB, Sarles HE, Remmers AR: Serum ferritin assay and bone-marrow iron stores in patients on maintenance hemodialysis. Kidney Int 17:237-241, 1980
10. 10. Cavill I: Diagnostic methods. Clin Haematol 11:259-273, 1982
11. 11. Macdougall IC, Cavill I, Hulme B, Bain B, Mcgregor E, Mckay P, Sandes E, Coles GA, Williams JD: Detection of functional iron deficiency during erythropoietin treatment: A new approach. BMJ 304:225-226, 1992
12. 12. Sunder-Plassman G, Hörl WH: Iron metabolism and iron substitution during erythropoietin therapy. Clin Invest 72(Suppl):S11-S15, 1994
13. 13. Schaefer RM, Schaefer L: The hypochromic red cell: A new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinat Med 23:83-88, 1995
14. 14. Braun J, Lindner K, Schreiber M, Heidler RA, Hörl WH: Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 12:1173-1181, 1997
15. 15. Sunder-Plassman G, Spitzauer S, Hörl WH: The dilemma of evaluating iron status in dialysis patients-limitation of available diagnostic procedures. Nephrol Dial Transplant 12:1575-1580, 1997
16. 16. Macdougall IC: Merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant 13:847-849, 1998
17. 17. Van Bockstaele DR, Peetermans ME: 1,3'-Diethyl-4,2'-quinolylthiacyanine iodide as a "Thiazole orange" analogue for nucleic acid staining. Cytometry 10:214-216, 1989
18. 18. Eschbach JW, Egrie JC, Downing MR, Brown JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316:73-78, 1987
19. 19. Van Wijck DB: Iron management during recombinant human erythropoietin therapy. Am J Kidney Dis 14(Suppl 1):9-13, 1989
20. 20. Kooistra MP, Van Es A, Struyvenberg A, Marx JJM: Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 79:634-639, 1991
21. 21. Kooistra MP, Niemantsverdriet EC, Van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJM: Iron absorption in erythropoietin-treated haemodialysed patients: Effects of iron availability, inflammation and aluminum. Nephrol Dial Transplant 13:82-88, 1988
22. 22. Means RT Jr, Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80:1639-1647, 1992
23. 23. Rogers J, Lacroix L, Durmowits G, Kasschau K, Andriotakis J, Bridges KR: The role of cytokines in the regulation of cytokine expression, in Progress in Iron Research, edited by Herschko C, Konijn AM, Aisen P, New York, Plenum Press, 1994, pp 127-132
24. 24. Tran TN, Eubanks SK, Schaffer KJ, Zhou CYJ, Linder MC: Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 90:4979-4986, 1997
25. 25. Saltissi D, Sauvage D, Westhuyzen J: Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Clin Nephrol 49:45-48, 1998
26. 26. Beguin Y, Huebers HA, Josephson B, Finch CA: Transferrin receptors in rat plasma. Proc Natl Acad Sci USA 85:637-640, 1988
27. 27. Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA: Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 75:102-107, 1990
28. 28. Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK: Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 52:217-222, 1997
29. 29. National Kidney Foundation DOQI. Am J Kidney Dis 30-4(Suppl 3):S218-S220, 1997
30. 30. Marti HR, Fischer S, Killer D, Burgi W: Can automated hematology analysers discriminate thalassemia from iron deficiency. Acta Haematol 78:180-183, 1987
31. 31. D'Onofrio G, Zini G, Ricerca BM, Mancini S, Mango G: Automated measurement of red blood cell microcytosis and hypochromia in iron deficiency and β-thalassemia trait. Arch Pathol Lab Med 116:84-89, 1992
32. 32. Robertson EP, Pollock A, Yauss KS, Chan LC: Use of Technicon H*1 technology in routine thalassemia screening. Med Lab Sci 49:259-264, 1992
33. 33. Bunyaratvej A, Fucharoen S, Greenbaum A, Mohandas N: Hydratation of red cells in α and β thalassemia differs: A useful approach to distinguish between these red cell phenotypes. Am J Clin Pathol 102:217-222, 1994
34. 34. Jimenez CV, Minchinele J, Ros J: New indices from the H*2 analyser improve differentiation between heterozygous β or δβ thalassemia and iron-deficiency anemia. Clin Lab Haem 17:151-155, 1995
35. 35. Bunyaratvej A, Bunyaratvej P: Measurements of cell volume and hemoglobin concentration of erythrocytes from hereditary ovalocytosis and hereditary spherocytosis. J Med Assoc Thai 75(Suppl 1):248-252, 1992
36. 36. Navarro JF, Macia ML: Hypochromic red cells as an indicator of iron deficiency. J Rheumatol 24:804-805, 1997
37. 37. Brugnara C, Kruskall MS, Johnstone RM: Membrane properties of erythrocytes in subject undergoing multiple blood donations with or without recombinant erythropoietin. Br J Haematol 84:118-130, 1993
38. 38. Mckay PJ, Stott DJ, Holyoake T, Hendry A, Mac Donald JB, Lucie NP: Use of the erythrogram in the diagnosis of iron deficiency in elderly patients. Acta Haematol 89:169-173, 1993